Alveritin (epoetin alfa biosimilar) / Alvartis - LARVOL DELTA

EHA 2021 | COMMANDS trial: luspatercept vs epoetin alfa in lower-risk MDS (VJHemOnc) - P3, N=NA; COMMANDS trial (NCT03682536); "Uwe Platzbecker, MD...updates on the Phase III COMMANDS trial (NCT03682536) investigating luspatercept in erythropoiesis-stimulating agents (ESAs)-naïve patients with lower-risk myelodysplastic syndromes (MDS) who are red blood cell transfusion dependent. Luspatercept is a currently registered treatment for myelodysplastic patients as a second-line treatment after ESA failure. The study is actively recruiting and it is hoped that results from the study will be available next year. This interview took place at the virtual European Hematology Association (EHA) Congress 2021."

Interview • P3 data • Video